Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study)

The publication proposes adding intraperitoneal serplulimab to a PRaG-based regimen.

Technology in cancer research & treatment · Jul 25, 2024
Original authors: Yingying Xu, Yuehong Kong, Yifu Ma, Meiling Xu, Jiabao Yang, Junjun Zhang, Rongzheng Chen, Guangqiang Chen, Zhihui Hong, Xiangrong Zhao, Chenyang Zhang, Pengfei Xing, Liyuan Zhang, Peifeng Zhao

Study protocol: planned research, not a report of completed treatment outcomes.

Who was studied?

Patients with advanced refractory solid tumors and malignant ascites.

What does the publication report?

A multicenter, single-arm study with dose finding followed by efficacy evaluation is proposed. It does not report completed trial results.

Safety findings

Dose-limiting toxicity evaluation is planned for phase I.

How should we interpret it?

This is a study protocol, not a report of treatment results. Planned enrollment and endpoints are not observed outcomes.

Read the original source

This independently written summary was checked against the publicly available abstract. It is not a translation of the full paper or a clinical recommendation.

Phase I/II Clinical Study of PRaG Regimen Combined With Intraperitoneal Infusion of PD-1 Inhibitor for Advanced Refractory Solid Tumors With Cancerous Ascites (PRaG4.0P Study) · DOI: 10.1177/15330338241264169 · PMID: 39051686

Educational reporting, not individualized medical advice. Discuss treatment decisions with your clinical team.